All eyes on Novo's new outlook on eve of 2021 report

On Wednesday morning, when Novo Nordisk presents its full-year financial results prior to the stock exchange opening, the attention of analysts and investors will be on the outlook for the new year, as growth isn’t expected to match 2021 levels due to production issues with obesity drug Wegovy.

Photo: Stine Tidsvilde

All eyes will be fixed on Novo Nordisk’s 2022 guidance when the company publicizes its full-year report on Wednesday morning.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu credits MDR milestone to fastidiousness

All of Medtech firm Ambu’s products already live up to the new EU rules for medical devices, something the firm attributes to a good sense of how much effort living up to the new legislation would require.

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs